Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 3 (2019)

Prescription preference of antidiabetic drugs among clinicians

Dr. Sayan Das, Dr. AV Tilak, Dr. Nimish Narkar, Dr. Suresh Dange, Dr. BT Rane and Dr. Shrikrishna Shende
Introduction: Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycaemia. The increased numbers of choices for treatment of DM have often left the practitioners without a clear pathway of therapy to follow. A practitioner cannot blindly follow a single protocol adapted from some guidelines. Thus, a prescription pattern among clinicians in Pimpri, Pune.
Aim & Objectives
•To study the overall utilization of various available therapies for diabetes mellitus
•To study the utilization pattern between monotherapy and combined therapies
Material & Methods: A cross sectional observational study for a period of 6 months among 100 clinicians/practitioners who treat patients of type 2 diabetes mellitus (T2DM) in Pimpri, Pune. It was a questionnaire based study. Institutional Ethics Committee (IEC) clearance was obtained before the start of the study. Written informed consent was obtained from all the subjects before participation and the questionnaire was provided to be filled by them.
Results: Overall metformin was the most preferred prescribed anti diabetic agent followed by sulphonylureas, thiazolidinediones, α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitors. Metformin + sulphonylureas is the most preferred combination therapy. The most preferred insulin preparations are insulin mixtard (30/70). The practitioners preferred a double drug therapy over monotherapy or a triple drug therapy for treatment of type 2 diabetes mellitus patients.
Pages: 59-63  |  944 Views  137 Downloads

The Pharma Innovation Journal
How to cite this article:
Dr. Sayan Das, Dr. AV Tilak, Dr. Nimish Narkar, Dr. Suresh Dange, Dr. BT Rane, Dr. Shrikrishna Shende. Prescription preference of antidiabetic drugs among clinicians. Pharma Innovation 2019;8(3):59-63.

Call for book chapter